IL18 and psoriasis: Recombinant human IL-18 binding protein, which neutralize IL-18 along with IL-37 had more success in experiments and clinical trials in psoriasis, rheumatoid arthritis, hemophagocytic lymphohistiocytosis, and adult onset Still disease (204).